Cargando…
Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
Autores principales: | Chen, Z, Wang, W, Cortes, J E, Liu, E, Miranda, R N, Zhao, C, Yuan, J, Lu, X, Yang, W, Ameri, M D, Kantarjian, H M, Medeiros, L J, Hu, S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916296/ https://www.ncbi.nlm.nih.gov/pubmed/27152845 http://dx.doi.org/10.1038/bcj.2016.27 |
Ejemplares similares
-
Impact of frontline treatment approach on outcomes of myeloid blast phase CML
por: Saxena, Kapil, et al.
Publicado: (2021) -
Prospective Analysis: Relative Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors
por: Sasaki, Koji, et al.
Publicado: (2015) -
Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity
por: Frietsch, Jochen J., et al.
Publicado: (2020) -
Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase
por: Chakraborty, S, et al.
Publicado: (2013) -
Pediatric chronic myeloid leukemia in myeloid blast crisis
por: Dey, Biswajit, et al.
Publicado: (2023)